AnaptysBio

blocks stack target climb build arrow meet

Biotech

AnaptysBio's PD-1 drug reduces rheumatoid arthritis in phase 2

All three doses hit the trial’s primary endpoint that showed a statistically significant change from baseline in disease activity after 12 weeks.

James Waldron Feb 12, 2025 9:57am

Person throwing piece of paper into full waste bin

Anaptys scraps atopic dermatitis asset after ph. 2 fail

Dec 11, 2024 11:02am

Anaptys picks up rival to Biogen autoimmune asset from Centessa

Nov 28, 2023 6:30am

Graphic of a number of arrows missing the bullseye on a target except for one arrow

Chasing Boehringer, Anaptys hits goal in skin disease phase 3

Oct 9, 2023 9:20am

dominoes fall series fail

AnaptysBio's HARP plays dud note, prompting rethink of strategy

Sep 1, 2022 8:05am

merger acquisition deal

Gilead makes $405M buy to compete with Lilly's BTLA program

Aug 4, 2022 11:46am